Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes

Mise à jour : Il y a 4 ans
Référence : NCT00974090

Femme et Homme

  • | Pays :
  • Japan
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The purpose of this study is to evaluate the safety and efficacy of MP-513 (Teneligliptin) in combination with Sulfonylurea in patients with type 2 Diabetes for 12 weeks administration and to evaluate the safety and efficacy of MP-513 in combination with Sulfonylurea with an extension treatment for up to 52 weeks.


Critère d'inclusion

  • Type 2 diabetes mellitus

Liens